Check out CKB's new cancer variant visual navigation! Learn more here.
The JAX-CKB team would like to send well wishes to everyone during this difficult time. We are working virtually to ensure our users continue to have access to up-to-date content. Questions or comments about CKB? Feel free to contact us at: email@example.com
CKB BOOST now has AMP/CAP/ASCO evidence level coding!
Vitrakvi (larotrectinib) approved regardless of tumor type for NTRK fusions, except with acquired resistance mutations! Need a list of resistance mutations? Visit ckbhome.jax.org and sign-up for CKB BOOST.